137 related articles for article (PubMed ID: 21914500)
1. Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II).
Gandjour A; Holler A; Dipl-Ges-Ök ; Adarkwah CC
Value Health; 2011; 14(6):812-7. PubMed ID: 21914500
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of implantable cardioverter-defibrillators.
Sanders GD; Hlatky MA; Owens DK
N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
Zwanziger J; Hall WJ; Dick AW; Zhao H; Mushlin AI; Hahn RM; Wang H; Andrews ML; Mooney C; Wang H; Moss AJ
J Am Coll Cardiol; 2006 Jun; 47(11):2310-8. PubMed ID: 16750701
[TBL] [Abstract][Full Text] [Related]
5. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials?
Coats AJ
Int J Cardiol; 2002 Jan; 82(1):1-5. PubMed ID: 11786150
[TBL] [Abstract][Full Text] [Related]
6. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
7. Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis.
Piccini JP; Al-Khatib SM; Myers ER; Anstrom KJ; Buxton AE; Peterson ED; Sanders GD
J Cardiovasc Electrophysiol; 2010 Jul; 21(7):791-8. PubMed ID: 20132397
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II.
Al-Khatib SM; Anstrom KJ; Eisenstein EL; Peterson ED; Jollis JG; Mark DB; Li Y; O'Connor CM; Shaw LK; Califf RM
Ann Intern Med; 2005 Apr; 142(8):593-600. PubMed ID: 15838065
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of captopril therapy after myocardial infarction.
Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
[TBL] [Abstract][Full Text] [Related]
10. Are MADIT II criteria for implantable cardioverter defibrillator implantation appropriate for Chinese patients?
Siu CW; Pong V; Ho HH; Liu S; Lau CP; Li SW; Tse HF
J Cardiovasc Electrophysiol; 2010 Mar; 21(3):231-5. PubMed ID: 19804551
[TBL] [Abstract][Full Text] [Related]
11. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II.
Goldenberg I; Gillespie J; Moss AJ; Hall WJ; Klein H; McNitt S; Brown MW; Cygankiewicz I; Zareba W;
Circulation; 2010 Sep; 122(13):1265-71. PubMed ID: 20837894
[TBL] [Abstract][Full Text] [Related]
12. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.
Sanders GD; Kong MH; Al-Khatib SM; Peterson ED
Am Heart J; 2010 Jul; 160(1):122-31. PubMed ID: 20598982
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
Smith T; Jordaens L; Theuns DA; van Dessel PF; Wilde AA; Hunink MG
Eur Heart J; 2013 Jan; 34(3):211-9. PubMed ID: 22584647
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
16. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.
Filion KB; Xie X; van der Avoort CJ; Dendukuri N; Brophy JM
Int J Technol Assess Health Care; 2009 Apr; 25(2):151-60. PubMed ID: 19331707
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
[TBL] [Abstract][Full Text] [Related]
18. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
[TBL] [Abstract][Full Text] [Related]
19. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
20. Enhancing specificity without sacrificing sensitivity: potential benefits of using microvolt T-wave alternans testing to risk stratify the MADIT-II population.
Cohen RJ
Card Electrophysiol Rev; 2003 Dec; 7(4):438-42. PubMed ID: 15071271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
